Switch to:
Also traded in: France, Germany, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 465.47
OTCPK:NICXF's Cash-to-Debt is ranked higher than
56% of the 982 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. OTCPK:NICXF: 465.47 )
Ranked among companies with meaningful Cash-to-Debt only.
OTCPK:NICXF' s Cash-to-Debt Range Over the Past 10 Years
Min: 35.54  Med: 1592.13 Max: 24712.5
Current: 465.47
35.54
24712.5
Equity-to-Asset 0.70
OTCPK:NICXF's Equity-to-Asset is ranked higher than
52% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. OTCPK:NICXF: 0.70 )
Ranked among companies with meaningful Equity-to-Asset only.
OTCPK:NICXF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.62  Med: 0.85 Max: 0.91
Current: 0.7
0.62
0.91
Interest Coverage N/A
OTCPK:NICXF's Interest Coverage is ranked lower than
58% of the 484 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OTCPK:NICXF: N/A )
Ranked among companies with meaningful Interest Coverage only.
OTCPK:NICXF' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: N/A Max: No Debt
Current: N/A
N/A
No Debt
Piotroski F-Score: 3
Altman Z-Score: 3.81
Beneish M-Score: -4.06
WACC vs ROIC
4.32%
-10.94%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -48650.00
OTCPK:NICXF's Operating Margin % is ranked lower than
97% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. OTCPK:NICXF: -48650.00 )
Ranked among companies with meaningful Operating Margin % only.
OTCPK:NICXF' s Operating Margin % Range Over the Past 10 Years
Min: -48650  Med: -2356.13 Max: -114.88
Current: -48650
-48650
-114.88
Net Margin % -118968.75
OTCPK:NICXF's Net Margin % is ranked lower than
98% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -84.10 vs. OTCPK:NICXF: -118968.75 )
Ranked among companies with meaningful Net Margin % only.
OTCPK:NICXF' s Net Margin % Range Over the Past 10 Years
Min: -118968.75  Med: -2197.71 Max: -134.58
Current: -118968.75
-118968.75
-134.58
ROE % -20.07
OTCPK:NICXF's ROE % is ranked higher than
62% of the 906 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. OTCPK:NICXF: -20.07 )
Ranked among companies with meaningful ROE % only.
OTCPK:NICXF' s ROE % Range Over the Past 10 Years
Min: -54.47  Med: -27.49 Max: -12.9
Current: -20.07
-54.47
-12.9
ROA % -12.64
OTCPK:NICXF's ROA % is ranked higher than
65% of the 991 Companies
in the Global Biotechnology industry.

( Industry Median: -30.78 vs. OTCPK:NICXF: -12.64 )
Ranked among companies with meaningful ROA % only.
OTCPK:NICXF' s ROA % Range Over the Past 10 Years
Min: -47.2  Med: -21.87 Max: -11.39
Current: -12.64
-47.2
-11.39
ROC (Joel Greenblatt) % -1753.15
OTCPK:NICXF's ROC (Joel Greenblatt) % is ranked lower than
69% of the 951 Companies
in the Global Biotechnology industry.

( Industry Median: -362.00 vs. OTCPK:NICXF: -1753.15 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OTCPK:NICXF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2845.25  Med: -1404.48 Max: -310.85
Current: -1753.15
-2845.25
-310.85
3-Year Revenue Growth Rate -67.80
OTCPK:NICXF's 3-Year Revenue Growth Rate is ranked lower than
89% of the 528 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. OTCPK:NICXF: -67.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OTCPK:NICXF' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -56.4 Max: 129.3
Current: -67.8
0
129.3
3-Year EBITDA Growth Rate -24.40
OTCPK:NICXF's 3-Year EBITDA Growth Rate is ranked lower than
78% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 0.80 vs. OTCPK:NICXF: -24.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OTCPK:NICXF' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -52.6  Med: -9.7 Max: 53.2
Current: -24.4
-52.6
53.2
3-Year EPS without NRI Growth Rate -28.90
OTCPK:NICXF's 3-Year EPS without NRI Growth Rate is ranked lower than
78% of the 554 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. OTCPK:NICXF: -28.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OTCPK:NICXF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -74.8  Med: -7.1 Max: 325
Current: -28.9
-74.8
325
GuruFocus has detected 2 Warning Signs with Nicox SA $OTCPK:NICXF.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OTCPK:NICXF's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology  
Compare:NAS:CNCE, NAS:CLDX, NAS:SVA, NAS:NVAX, NAS:SELB, NAS:MRUS, NAS:CRBP, OTCPK:PTCHF, NAS:NERV, NAS:BSTC, NAS:EDGE, AMEX:BTX, NAS:CRIS, NAS:PETX, NAS:OCUL, NAS:ASMB, NAS:OVID, NAS:IDRA, OTCPK:RCAR, OTCPK:VRSO » details
Traded in other countries:COX.France, NXOA.Germany, 0RCQ.UK,
Headquarter Location:France
Nicox SA is a biopharmaceutical company. It provides opthalmic products in United States and Europe. It is engaged in the nitric oxide-donating technology.

Ratios

vs
industry
vs
history
PB Ratio 2.74
NICXF's PB Ratio is ranked higher than
65% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. NICXF: 2.74 )
Ranked among companies with meaningful PB Ratio only.
NICXF' s PB Ratio Range Over the Past 10 Years
Min: 0.53  Med: 2.29 Max: 12
Current: 2.74
0.53
12
Current Ratio 2.29
NICXF's Current Ratio is ranked lower than
71% of the 981 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. NICXF: 2.29 )
Ranked among companies with meaningful Current Ratio only.
NICXF' s Current Ratio Range Over the Past 10 Years
Min: 1.4  Med: 8.28 Max: 16.29
Current: 2.29
1.4
16.29
Quick Ratio 2.29
NICXF's Quick Ratio is ranked lower than
67% of the 980 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NICXF: 2.29 )
Ranked among companies with meaningful Quick Ratio only.
NICXF' s Quick Ratio Range Over the Past 10 Years
Min: 1.37  Med: 8.28 Max: 16.26
Current: 2.29
1.37
16.26
Days Inventory 53.58
NICXF's Days Inventory is ranked higher than
76% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: 131.03 vs. NICXF: 53.58 )
Ranked among companies with meaningful Days Inventory only.
NICXF' s Days Inventory Range Over the Past 10 Years
Min: 53.58  Med: 255.01 Max: 652.52
Current: 53.58
53.58
652.52
Days Sales Outstanding 2.00
NICXF's Days Sales Outstanding is ranked higher than
96% of the 625 Companies
in the Global Biotechnology industry.

( Industry Median: 64.26 vs. NICXF: 2.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
NICXF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.34  Med: 97.93 Max: 16490.37
Current: 2
0.34
16490.37
Days Payable 92.08
NICXF's Days Payable is ranked higher than
68% of the 432 Companies
in the Global Biotechnology industry.

( Industry Median: 54.41 vs. NICXF: 92.08 )
Ranked among companies with meaningful Days Payable only.
NICXF' s Days Payable Range Over the Past 10 Years
Min: 92.08  Med: 2837.79 Max: 51942.31
Current: 92.08
92.08
51942.31

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -18.80
NICXF's 3-Year Average Share Buyback Ratio is ranked lower than
67% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. NICXF: -18.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NICXF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -18.8  Med: -13.9 Max: -0.8
Current: -18.8
-18.8
-0.8

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 182.86
NICXF's Price-to-Median-PS-Value is ranked lower than
99% of the 667 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. NICXF: 182.86 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NICXF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.28  Med: 1.14 Max: 191.67
Current: 182.86
0.28
191.67
Earnings Yield (Greenblatt) % -2.92
NICXF's Earnings Yield (Greenblatt) % is ranked higher than
65% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -7.96 vs. NICXF: -2.92 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NICXF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -4706.2  Med: -11.85 Max: 11508.9
Current: -2.92
-4706.2
11508.9

More Statistics

Revenue (TTM) (Mil) $0.02
EPS (TTM) $ -0.92
Beta1.00
Short Percentage of Float0.00%
52-Week Range $7.88 - 14.75
Shares Outstanding (Mil)25.61
» More Articles for NICXF

Headlines

Articles On GuruFocus.com
Autonomous Driving Offers No Easy Path for Investors Jun 27 2017 
Berkshire Hathaway Invests in STORE Capital Jun 27 2017 
Credit Suisse Income Fund Announces Monthly Dividend Jun 27 2017 
Seeking Value in the Oil Industry: Civeo Jun 27 2017 
Seeking Value in the Grocery Goods Distributor Jun 27 2017 
GAMCO Analyst: Is VMware a Compelling Investment Idea in Data Infrastructure? Jun 26 2017 
Gabelli TV: 2017 American Water Works Annual Conference Recap Jun 26 2017 
Monthly Dividend Stocks to Pay Your Bills Jun 26 2017 
The Rubicon Project: Who Is Selling and Why It's Creating a Bargain Price Jun 26 2017 
Sports, Stocks and the Magic Quadrants Jun 26 2017 

More From Other Websites
Nicox to present at the 2017 BIO International Convention Jun 15 2017
NICOX : Issuing and admission to trading on the Euronext regulated market in Paris of 597,897 new... Jun 08 2017
Nicox: Issuing and admission to trading on the Euronext regulated market in Paris of 597,897 new... Jun 08 2017
NICOX : Number of voting rights as of May 31, 2017 Jun 01 2017
Nicox: Report on the termination of the liquidity agreement with Gilbert Dupont Jun 01 2017
Nicox receives FDA approval of ZERVIATE1 (cetirizine ophthalmic solution) 0.24% May 31 2017
Ms. Lauren P. Silvernail appointed to Nicox Board of Directors May 17 2017
Nicox announces the presentation of scientific data on NCX 667 at ARVO 2017 May 09 2017
NICOX : Total number of voting rights as of April 30. 2017 May 02 2017
Nicox first quarter 2017 business update and cash position Apr 27 2017
Nicox announces PDUFA date for ZERVIATE NDA Apr 11 2017
NICOX : Number of voting rights as of April 5, 2017 Apr 05 2017
NICOX : Number of voting rights as of March 31, 2017 Apr 03 2017
Nicox: Business Update and 2016 Financial Results Mar 31 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}